XML 34 R12.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Revenues | 12 Months Ended
--- | ---
Dec. 31, 2024
Revenue from Contract with Customer [Abstract] |
Revenues | Revenues We operate our business in one operating segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW product sales relates to products sold in Europe. Revenues were as follows (in millions):
|  | Year ended December 31, 2024 |  | Year ended December 31, 2023 |  | Year ended December 31, 2022
|  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total
Prolia |  | $ | 2,885 |  |  | $ | 1,489 |  |  | $ | 4,374 |  |  | $ | 2,733 |  |  | $ | 1,315 |  |  | $ | 4,048 |  |  | $ | 2,465 |  |  | $ | 1,163 |  |  | $ | 3,628 |
ENBREL |  | 3,288 |  |  | 28 |  |  | 3,316 |  |  | 3,650 |  |  | 47 |  |  | 3,697 |  |  | 4,044 |  |  | 73 |  |  | 4,117 |
XGEVA |  | 1,507 |  |  | 718 |  |  | 2,225 |  |  | 1,527 |  |  | 585 |  |  | 2,112 |  |  | 1,480 |  |  | 534 |  |  | 2,014 |
Repatha |  | 1,139 |  |  | 1,083 |  |  | 2,222 |  |  | 793 |  |  | 842 |  |  | 1,635 |  |  | 608 |  |  | 688 |  |  | 1,296 |
Otezla |  | 1,699 |  |  | 427 |  |  | 2,126 |  |  | 1,777 |  |  | 411 |  |  | 2,188 |  |  | 1,886 |  |  | 402 |  |  | 2,288 |
TEPEZZA(1) |  | 1,835 |  |  | 16 |  |  | 1,851 |  |  | 441 |  |  | 7 |  |  | 448 |  |  | — |  |  | — |  |  | — |
EVENITY |  | 1,131 |  |  | 432 |  |  | 1,563 |  |  | 809 |  |  | 351 |  |  | 1,160 |  |  | 533 |  |  | 254 |  |  | 787 |
KYPROLIS |  | 948 |  |  | 555 |  |  | 1,503 |  |  | 921 |  |  | 482 |  |  | 1,403 |  |  | 850 |  |  | 397 |  |  | 1,247 |
Nplate |  | 970 |  |  | 486 |  |  | 1,456 |  |  | 996 |  |  | 481 |  |  | 1,477 |  |  | 848 |  |  | 459 |  |  | 1,307 |
Aranesp |  | 386 |  |  | 956 |  |  | 1,342 |  |  | 452 |  |  | 910 |  |  | 1,362 |  |  | 521 |  |  | 900 |  |  | 1,421 |
BLINCYTO |  | 800 |  |  | 416 |  |  | 1,216 |  |  | 566 |  |  | 295 |  |  | 861 |  |  | 336 |  |  | 247 |  |  | 583 |
KRYSTEXXA(1) |  | 1,185 |  |  | — |  |  | 1,185 |  |  | 272 |  |  | — |  |  | 272 |  |  | — |  |  | — |  |  | — |
Vectibix |  | 519 |  |  | 526 |  |  | 1,045 |  |  | 461 |  |  | 523 |  |  | 984 |  |  | 396 |  |  | 497 |  |  | 893 |
TEZSPIRE |  | 972 |  |  | — |  |  | 972 |  |  | 567 |  |  | — |  |  | 567 |  |  | 170 |  |  | — |  |  | 170 |
Other products(2) |  | 4,037 |  |  | 1,593 |  |  | 5,630 |  |  | 3,307 |  |  | 1,389 |  |  | 4,696 |  |  | 3,606 |  |  | 1,444 |  |  | 5,050 |
Total product sales(3) |  | 23,301 |  |  | 8,725 |  |  | 32,026 |  |  | 19,272 |  |  | 7,638 |  |  | 26,910 |  |  | 17,743 |  |  | 7,058 |  |  | 24,801 |
Other revenues |  | 562 |  |  | 836 |  |  | 1,398 |  |  | 534 |  |  | 746 |  |  | 1,280 |  |  | 852 |  |  | 670 |  |  | 1,522 |
Total revenues |  | $ | 23,863 |  |  | $ | 9,561 |  |  | $ | 33,424 |  |  | $ | 19,806 |  |  | $ | 8,384 |  |  | $ | 28,190 |  |  | $ | 18,595 |  |  | $ | 7,728 |  |  | $ | 26,323 |
____________ (1) TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and include product sales in the periods after the acquisition date. (2) Consists of product sales of our non-principal products. (3) Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2024, 2023 and 2022. In the United States, we sell primarily to pharmaceutical wholesale distributors that we use as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance. For each of the years ended December 31, 2024, 2023 and 2022, we had product sales to three customers that individually accounted for more than 10% of total revenues. For the year ended December 31, 2024, on a combined basis, these customers accounted for 77% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):
| Years ended December 31,
| 2024 |  | 2023 |  | 2022
McKesson Corporation: |  |  |  |  |
Gross product sales | $ | 22,173 |  |  | $ | 19,035 |  |  | $ | 17,305 |
% of total gross revenues | 33 | % |  | 33 | % |  | 35 | %
Cencora, Inc.: |  |  |  |  |
Gross product sales | $ | 18,387 |  |  | $ | 16,625 |  |  | $ | 15,443 |
% of total gross revenues | 27 | % |  | 29 | % |  | 31 | %
Cardinal Health, Inc.: |  |  |  |  |
Gross product sales | $ | 11,278 |  |  | $ | 9,775 |  |  | $ | 8,319 |
% of total gross revenues | 17 | % |  | 17 | % |  | 16 | %
As of December 31, 2024 and 2023, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 70% and 75%, respectively, of net trade receivables on a combined basis. As of December 31, 2024 and 2023, 26% and 22%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2024 and 2023, was not material.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration